Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in ...

In CAR-T therapy, CD19 is now the most extensively used target. It has been confirmed to be effective and safe for the treatment of CLL, B-ALL and B cell lymphoma. FMC63, an IgG2a mouse monoclonal ...

which directs them to CD19 antigens on B-cell cancers. In the absence of the antibody, the CAR-T cells are dormant. The first readout from an ongoing phase 1 study reveals that, out of nine ...

CHICAGO, January 29, 2025--(BUSINESS WIRE)--VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Catalent global cell therapy and plasmid DNA vice-president Delara ... GLPG5101 is an anti-cluster of differentiation 19 (CD19)/4-1BB CAR-T candidates, designed to be administered in a single ...